Pliant Therapeutics, Inc.

NasdaqGS:PLRX 株式レポート

時価総額:US$648.5m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Pliant Therapeutics 過去の業績

過去 基準チェック /06

Pliant Therapeuticsの収益は年間平均-43.3%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 減少しています。収益は年間0.4% 54.4%割合で 減少しています。

主要情報

-43.3%

収益成長率

25.4%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率-54.4%
株主資本利益率-39.0%
ネット・マージン-68,848.0%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21
We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow

Dec 02

収支内訳

Pliant Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:PLRX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 240-17159136
31 Dec 232-16158128
30 Sep 234-15558120
30 Jun 235-14452112
31 Mar 2310-13346105
31 Dec 2210-1234097
30 Sep 2210-1133491
30 Jun 2210-1093287
31 Mar 227-1033080
31 Dec 218-972878
30 Sep 2110-922577
30 Jun 2113-812272
31 Mar 2115-752071
31 Dec 2042-421766
30 Sep 2094181560
30 Jun 2090191354
31 Mar 2086201250
31 Dec 1957-71147
31 Mar 190-43831
31 Dec 180-35724

質の高い収益: PLRXは現在利益が出ていません。

利益率の向上: PLRXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: PLRXは利益が出ておらず、過去 5 年間で損失は年間43.3%の割合で増加しています。

成長の加速: PLRXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PLRXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。


株主資本利益率

高いROE: PLRXは現在利益が出ていないため、自己資本利益率 ( -39.04% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘